Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 2, 2009, Pages 219-225

  Rudolfsson, Stina Häggström ^a   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Androgen withdrawal; Angiogenesis; Hypoxia; Prostate; VEGF

Indexed keywords

ANDROGEN; CYTOTOXIC AGENT; OXYGEN; TESTOSTERONE; ANTIANDROGEN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANDROGEN THERAPY; ANGIOGENESIS; BLOOD VESSEL; CANCER THERAPY; CASTRATION; DRUG EFFICACY; EPITHELIUM CELL; HUMAN; HYPOXEMIA; HYPOXIA; HYPOXIC CELL; NONHUMAN; PROSTATE CANCER; REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; VASCULARIZATION; ANIMAL; CELL DEATH; CELL HYPOXIA; CLINICAL TRIAL; DISEASE COURSE; DRUG DELIVERY SYSTEM; MALE; ORCHIECTOMY; PATHOPHYSIOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 64349118644     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220802626249     Document Type: Review

References (87)

1. Parker C, Milosevic M, Toi A, et al. Polarographic electrode study of tumour oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004 ; 58 (3): 750-757 (Pubitemid 38221131)
2. Cvetkovic D, Movsas B, Dicker AP, et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001 ; 57 (4): 821-825
3. Movsas B, Chapman JD, Greenberg RE, et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO2 study. Cancer 2000 ; 89 (9): 2018 -24 ••Study showing that hypoxia is linked to tumour angiogenesis in prostate cancer.
4. Movsas B, Chapman JD, Hanlon AL, et al. Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. Am J Clin Oncol 2001 ; 24 (5): 458-461 (Pubitemid 32959102)
5. Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1 α is an early event in prostate carcinogenesis. Cancer Detect Prev 2004 ; 28 (2): 88-93 (Pubitemid 38448745)
6. Yeh KA, Biade S, Lanciano RM, et al. Polarographic needle electrode measurements of oxygen in rat prostate carcinomas: accuracy and reproducibility. Int J Radiat Oncol Biol Phys 1995 ; 33 (1): 111-118
7. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003 ; 195 : 1-16 (Pubitemid 36603331)
8. Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev 2008 ; 34 (4): 313-327
9. Carnell DM, Smith RE, Daley FM, et al. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys 2006 ; 65 (1): 91-99
10. Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008 ; 9 (4): 342-351
11. Salnikow K, Costa M, Figg WD, Blagosklonny MV. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res 2000 ; 60 (20): 5630-5634 (Pubitemid 30808293)
12. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002 ; 2 (1): 38-47 (Pubitemid 37328806)
13. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003 ; 20 (3): 237-250 (Pubitemid 36513228)
14. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996 ; 379 (6560): 88-91 (Pubitemid 26008141)
15. Yu JL, Coomber BL, Kerbel RS. A paradigm for therapy-induced microenvironmental changes in solid tumours leading to drug resistance. Differentiation 2002 ; 70 (9-10): 599-609 (Pubitemid 36194324)
16. Ghafar MA, Anastasiadis AG, Chen MW, et al. Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate 2003 ; 54 (1): 58 -67 • Experimental evidence that hypoxia makes prostate tumours more aggressive. (Pubitemid 36043837)
17. Butterworth KT, McCarthy HO, Devlin A, et al. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int J Cancer 2008 ; 123 (4): 760 -8 • Experimental evidence that hypoxia makes prostate tumours more aggressive.
18. Alqawi O, Wang HP, Espiritu M, Singh G. Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells. Free Radic Res 2007 ; 41 (7): 788 -97 • Experimental evidence that hypoxia makes prostate tumours more aggressive.
19. Krishnamachary B, Semenza GL. Analysis of hypoxia-inducible factor 1 α expression and its effects on invasion and metastasis. Methods Enzymol 2007 ; 435 : 347-354
20. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007 ; 26 (2): 225-239
21. Semensa GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003 ; 3 : 721-732 (Pubitemid 37328811)
22. Rudolfsson SH, Bergh A. Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1 α. J Endocrinol 2008 ; 196 (1): 11-19 (Pubitemid 351234567)
23. Hoskin PJ, Carnell DM, Taylor NJ, et al. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys 2007 ; 68 (4): 1065-1071 (Pubitemid 47048571)
24. Berger AP, Horninger W, Bektic J, et al. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease? BJU Int 2006 ; 98 : 587 -90 • Study suggesting a link between vascular and prostate diseases. (Pubitemid 44185881)
25. Harvey H. A unifying hypthesis that links benign prostate hyperplasia and prostatic intraepithelial neoplasia with prostate cancer. Pathol Res Pract 1995 ; 191 : 924 -34 • Study suggesting a link between vascular and prostate diseases.
26. Ghafar MA, Puchner PJ, Anastasiadis AG, et al. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep 2002 ; 3 : 292 -6 • Study suggesting a link between vascular and prostate diseases.
27. Hager M, Mikuz G, Bartsch G, et al. The association between local atherosclerosis and prostate cancer. BJU Int 2007 ; 99 (1): 46 -8 • Study suggesting a link between vascular and prostate diseases.
28. Tsuru N, Kurita Y, Masuda H, et al. Role of Doppler ultrasound and resistive index in benign prostatic hypertrophy. Int J Urol 2002 ; 9 (8): 427-430
29. Isaacs JT, Furuya Y, Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostate tissue. Semin Cancer Biol 1994 ; 5 : 391-400 (Pubitemid 124006792)
30. Kurita T, Wang YZ, Donjacour AA, et al. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 2001 ; 8 (2): 192 -200 •• Study showing that castration works through effects in the stroma.
31. Johansson A, Rudolfsson SH, Wikström P, Bergh A. Altered levels of angiopoietin 1 and tie 2 are associated with androgen-regulated vascular regression and growth in the ventral prostate in adult mice and rats. Endocrinology 2005 ; 146 : 3463-3470 (Pubitemid 41058119)
32. Johansson A, Jones J, Pietras K, et al. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. Prostate 2007 ; 67 (15): 1664-1676 (Pubitemid 350036952)
33. Ohlson N, Wikström P, Stattin P, Bergh A. Cell proliferation and apoptosis in prostate tumours and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 2005 ; 62 : 307-315 (Pubitemid 40224136)
34. Halin S, Hammarsten P, Wikström P, Bergh A. Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate 2007 ; 67 (4): 370-377 (Pubitemid 46341077)
35. Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001 ; 35 (6): 437-452 (Pubitemid 34066732)
36. Lekås E, Johansson M, Widmark A, et al. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997 ; 25 : 309 -14 •• First study showing that castration rapidly reduces blood flow. (Pubitemid 27461601)
37. Shabsigh A, Chang DT, Heitjan DF, et al. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998 ; 36 : 201 -6 •• First study showing that castration rapidly induces endothelial cell death. (Pubitemid 28341133)
38. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997 ; 3 (12 Pt 1): 2507-2511 (Pubitemid 28133175)
39. Häggström S, Wikström P, Bergh A, Damber JE. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 1998 ; 36 (2): 71-79 (Pubitemid 28311310)
40. Lekås E, Engstrand C, Bergh A, Damber JE. Transient ischemia induces apoptosis in the ventral prostate of the rat. Urol Res 1999 ; 27 (3): 174-179 (Pubitemid 29287595)
41. Buttyan R, Ghafar MA, Shabsigh A. The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol 2000 ; 10 : 415-420 (Pubitemid 30690912)
42. Shabsigh A, Ghafar MA, de la Taille A, et al. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 2001 ; 81 (3): 437 -44 •• First study showing that castration results in prostate tissue hypoxia.
43. Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumour angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001 ; 165 (2): 688-693 (Pubitemid 32060501)
44. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumour: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998 ; 95 (18): 10820 -5 • First study showing that castration may work through effects in the vasculature in prostate cancer.
45. Frost GI, Lustgarten J, Dudouet B, et al. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration. Microvasc Res 2005 ; 69 (1-2): 1-9 (Pubitemid 40410462)
46. Hammarsten P, Halin S, Wikstöm P, et al. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 2006 ; 12 (24): 7431-7436 (Pubitemid 46095418)
47. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al. Tumour oxygenation in hormone-dependent tumours during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000 ; 60 (16): 4556-4560 (Pubitemid 32103640)
48. Montironi R, Bartels PH, Thompson D, et al. Androgen-deprived prostate adenocarcinoma: evaluation of treatment-related changes versus no distinctive treatment effect with a Bayesian belief network. A methodological approach. Eur Urol 1996 ; 30 (3): 307-315 (Pubitemid 26362871)
49. Matsushima H, Goto T, Hosaka Y, et al. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 1999 ; 85 (8): 1822-1827 (Pubitemid 29169685)
50. Häggström S, Stattin P, Wikström P, et al. Castration induced reduction of vascular endothelial growth factor expression in non-malignant human prostate tissue is lost in advanced prostate cancer. Br J Urol Int 2001 ; 88 : 110-116 (Pubitemid 33755052)
51. Gleave ME, Zellweger T, Chi K, et al. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs 2002 ; 20 (2): 145-158 (Pubitemid 34632652)
52. Westin P, Stattin P, Damber JE, Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumours. Am J Pathol 1995 ; 146 (6): 1368-1375
53. Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 1999 ; 187 (2): 237-241 (Pubitemid 29037054)
54. Wikström P, Lindahl C, Bergh A. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate 2005 ; 62 (2): 148-164 (Pubitemid 40096781)
55. Gingrich JR, Barrios RJ, Katten MW, et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997 ; 57 : 4687-4691 (Pubitemid 27468967)
56. Rothermund CA, Gopalakrishnan VK, Eudy JD, Vishwanatha JK. Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. BMC Urol 2005 ; 5 : 5 . Pubished online 24 march 2005, doi:10.1186/1471-2490-5-5 (Pubitemid 40594689)
57. Bakin RE, Gioeli D, Sikes RA, et al. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003 ; 63 (8): 1981-1989 (Pubitemid 36460867)
58. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994 ; 54 : 5474-5478 (Pubitemid 24978134)
59. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002 ; 277 : 7076-7085 (Pubitemid 34959964)
60. Mabjeesh NJ, Willard MT, Frederickson CE, et al. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3 ? -kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003 ; 9 : 2416-2425 (Pubitemid 36842080)
61. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007 ; 74 (2-3): 72 -84 •• Description of the concept of vascular normalization.
62. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008 ; 8 (8): 579-591
63. Skov K, Adomat H, Bowden M, et al. Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages. Radiat Res 2004;162(5):547-553 (Pubitemid 39600543)
64. Yapp DT, Woo J, Kartono A, et al. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography. BJU Int 2007 ; 99 (5): 1154-1160
65. Milosevic M, Chung P, Parker C, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 2007 ; 67 (13): 6022-6025 (Pubitemid 47037480)
66. Okihara K, Watanabe H, Kojima M. Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging. Ultrasound Med Biol 1999 ; 25 (1): 89-94 (Pubitemid 29013446)
67. Huang ST, Hsieh ML. Evaluation of resistance index in patients with prostate cancer. Anticancer Res 2008 ; 28 (4A): 1985-1988
68. Franck-Lissbrant I, Häggström S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular re growth in the ventral prostate in castrated adult rats. Endocrinology 1998 ; 139 (2): 451-456 (Pubitemid 28513188)
69. Lissbrant IF, Hammarsten P, Lissbrant E, et al. Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt (1-3) IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate 2004 ; 58 : 57-65
70. Dor Y, Proat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 2001 ; 280 : C1367 -74 (Pubitemid 32553191)
71. Giordano FJ, Johnson RS. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Gene Dev 2001 ; 11 : 35-40 (Pubitemid 32119275)
72. Lee YM, Jeong CH, Koo SY, et al. Determination of hypoxic regions by hypoxia marker in developing mouse embryos in vivo: a possible signal for vessel development. Dev Dyn 2001 ; 220 : 175-186 (Pubitemid 32107819)
73. Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 1998 ; 139 : 441-442 (Pubitemid 28513186)
74. Park SY, Kim YJ, Gao AC, et al. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 2006 ; 66 (10): 5121 -9 •• First study showing that hypoxia makes AR supersensitive to androgens.
75. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008 ; 68 (15): 6407 -15 • Study showing that tumour androgen levels are rather unaffected by castration.
76. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008 ; 68 (11): 4447 -54 • Study showing that tumour androgen levels are rather unaffected by castration.
77. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007 ; 26 (2): 341-352
78. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996 ; 56 (19): 4509-4515 (Pubitemid 26330463)
79. Hara I, Miyake H, Yamada Y, et al. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate. Int J Urol 2002 ; 9 (6): 322-328 (Pubitemid 34779716)
80. Eigl BJ, Eggener SE, Baybik J, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005;11(13):4905-4911 (Pubitemid 41557211)
81. Tang Y, Khan MA, Goloubeva O, et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006 ; 12 (1): 169-174 (Pubitemid 43166191)
82. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004 ; 4 (6): 437-447 (Pubitemid 38745529)
83. Hammarsten P, Halin S, Wikstöm P, et al. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 2006 ; 12 (24): 7431-7436 (Pubitemid 46095418)
84. Ahn GO, Brown M. Targeting tumors with hypoxia-activated cytotoxins. Front Biosci 2007 ; 12 : 3483-3501
85. Wei MQ, Mengesha A, Good D, Anné J. Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 2008 ; 259 (1): 16-27 (Pubitemid 350245421)
86. Marcu L, Olver I. Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol 2006 ; 1 (1): 71-79
87. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol 2007 ; 19 : 427-442 (Pubitemid 46995614)